@entity1289 inhibitors in @entity712 --switching from XXXX to @entity4687 .

@entity1 @entity4688 @entity712 @entity1289 @entity4687
Although @entity1289 inhibitors have demonstrated their beneficial effects in @entity712 , whether different agents may induce different benefits remains unclear. We designed an open, sequential, prospective study switching @entity712 @entity1 receiving @entity4688 to @entity4687 which has been reported to be longer acting and better tolerated. The objective of the study was to find out if clinical and functional status could be further improved by changing from @entity4688 30 mg daily to a @entity4687 4 mg daily. Assessments of clinical status, echocardiography and nuclear ventriculography were performed at baseline under @entity4688 (30 mg mean dose (b.i.d.)), then 6 and 12 months after the switch to @entity4687 (4 mg/day mean dose). Thirty-one @entity1 were included (90% @entity1 , aged 56.5 +/- 11.8 years, mean radionuclide left ventricular (LV) ejection fraction 22.4 +/- 8.5 %). After 6 months of treatment, NYHA functional class was significantly improved; the percentage of @entity1 in class I increased to 57% after @entity4687 versus 20% at baseline (p < 0.001), and 50% of the total study population gained at least one NYHA class. After 12 months of treatment, 80% of the @entity1 were in NYHA class I. Blood pressure decreased significantly with a good tolerance at 6 months and then remained stable. After 12 months of treatment, significant reductions of LV end-diastolic diameter (61.4 +/- 5.3 vs. 64.5 +/- 6.5 mm; p = 0.001) and LV mass index (143.3 +/- 21.5 vs. 164.2 +/- 40.2 g/m2; p < 0.001) were observed, reflecting a positive effect on the LV remodelling process. Despite some limitations, because it is of an open-label design with a small number of @entity1 , our study found significant differences in clinical and objective parameters in @entity712 @entity1 switched from @entity4688 to @entity4687 . The prognostic significance of these findings remains to be investigated.
